Table 1: Selection, Design &
Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design &
Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design &
Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design &
Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design &
Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design &
Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials
of T - Vec Table 8: Clinical Trials
of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials
of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview
of Oncolytic Viruses by Development
Phase & Virus Family Table 14: Profile
of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design
of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications
of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies
of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies
of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies
of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern
of Transgenes in Oncolytic Viruses in Relation to Development
Phase Tables 21a and 21b: Indications and Frquency and Way
of Administration
of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development
of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio
of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests
of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources
of Technology Table 26: Second Generation Oncology Virus Companies and their Sources
of Technology Table 27: Third Generation Oncology Virus Companies and their Sources
of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources
of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions
This initial
phase, which is funded with the TIFIA Loan, includes (i) the
construction of two reversible lanes with associated exit / entrance ramps between Valley View Lanes and Turbeville Road; (ii) the
construction of managed lanes from south
of IH35E — IH635 interchange to Valley View Lane; (iii) reconfiguration and rehabilitation
of general purpose lanes from IH635 to Corinth Parkway; (iv) the
construction of direct connectors to Sam Rayburn Tollway; (v) the reconfiguration and / or widening
of general purpose lanes and the
construction of an additional general purpose lane in each direction from Sam Rayburn Tollway to US380; (vi) the
construction, reconstruction, widening or rehabilitation
of various frontage roads, interchanges, and bridges; (vii) the
construction of a collector - distributor system between President George Bush Turnpike and Sam Rayburn Tollway; (viii) the
construction of a new bridge and re-purposing
of the existing bridge over Lake Lewisville; and (ix) associated mitigation projects.